INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.

Smit E, F; C, Dooms; J, Raskin; E, Nadal; LM, Tho; X, Le; J, Mazieres; Hin H, S; M, Morise; Zhu V, W; D, Tan; Holmberg K, H; B, Ellers-Lenz; S, Adrian; S, Brutlach; KM, Schumacher; N, Karachaliou; YL, Wu

doi:10.2217/fon-2021-1406

Public

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.

Shared by NobleBlocks on Dec 17, 2021 • 12:00 AM UTC

Authors:

F Smit E

Dooms C

Raskin J

Abstract

MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibitor, such as tepotinib, an oral, high...

Subject

non-small-cell lung cancer

Met Amplification

Egfr Tyrosine Kinase Inhibitors

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!